- Home
- CTOR vs RGLS Comparison
CTOR vs RGLS Comparison
Compare CTOR & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- RGLS
- Stock Information
- Founded
- CTOR 2021
- RGLS 2007
- Country
- CTOR United States
- RGLS United States
- Employees
- CTOR N/A
- RGLS N/A
- Industry
- CTOR
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- RGLS Health Care
- Exchange
- CTOR NYSE
- RGLS Nasdaq
- Market Cap
- CTOR 126.2M
- RGLS 102.8M
- IPO Year
- CTOR N/A
- RGLS 2012
- Fundamental
- Price
- CTOR $1.55
- RGLS $1.62
- Analyst Decision
- CTOR Strong Buy
- RGLS Strong Buy
- Analyst Count
- CTOR 1
- RGLS 6
- Target Price
- CTOR $6.00
- RGLS $10.33
- AVG Volume (30 Days)
- CTOR 87.9K
- RGLS 283.1K
- Earning Date
- CTOR 08-12-2024
- RGLS 11-07-2024
- Dividend Yield
- CTOR N/A
- RGLS N/A
- EPS Growth
- CTOR N/A
- RGLS N/A
- EPS
- CTOR N/A
- RGLS N/A
- Revenue
- CTOR N/A
- RGLS N/A
- Revenue This Year
- CTOR N/A
- RGLS N/A
- Revenue Next Year
- CTOR N/A
- RGLS N/A
- P/E Ratio
- CTOR N/A
- RGLS N/A
- Revenue Growth
- CTOR N/A
- RGLS N/A
- 52 Week Low
- CTOR $1.53
- RGLS $1.08
- 52 Week High
- CTOR $49.00
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- RGLS 50.35
- Support Level
- CTOR N/A
- RGLS $1.54
- Resistance Level
- CTOR N/A
- RGLS $1.65
- Average True Range (ATR)
- CTOR 0.00
- RGLS 0.10
- MACD
- CTOR 0.00
- RGLS 0.01
- Stochastic Oscillator
- CTOR 0.00
- RGLS 70.59
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.